אַנטיטרוסט
אנטיטראסט: קאמיסיע זוכט באַמערקונגען איבער # פארבאנדן באפעלן פון # אספען צו רעדוצירן די פרייזן פאר זעקס נישט-פאטענט קענסער מעדיצינען מיט 73% צו באהאנדלען די קאמיסיע'ס זארגן איבער איבערצוגן פרייזן
The European Commission invites comments from all interested parties on commitments offered by Aspen to address the Commission's concerns over excessive pricing. Aspen proposes to reduce its prices in Europe for six critical cancer medicines by 73% on average. In addition, Aspen proposes to ensure the continued supply of these off-patent medicines for a significant period. Following a formal investigation opened on 15 מאי 2017, the Commission has serious concerns that Aspen has been abusing its dominant position in numerous national markets by charging excessive prices for critical off-patent cancer medicines. Aspen's practices concern a number of cancer medicines mainly used in the treatment of leukaemia and other haematological cancers. Aspen's behaviour may be in breach of the EU's antitrust rules.
The Commission invites all interested parties to submit their views on Aspen's proposed commitments within two months from their publication in the באַאַמטער דזשאָורנאַל. Taking into account all comments received, the Commission will then take a final view as to whether the commitments sufficiently address competition concerns. If this is the case, the Commission may adopt a decision making the proposed commitments legally binding on Aspen under Article 9 of the EU's antitrust Regulation (Council Regulation 1/2003).
Executive Vice President Margrethe Vestager, in charge of competition policy, said: “Pharmaceutical companies often bring innovative medicines to the market and they should be rewarded for that. However, they sometimes also use their dominant position to increase prices of old but critical medicines by several hundred percent without any real justification. The Commission has concerns that Aspen's conduct in this case amounts to excessive pricing by a dominant firm, which is prohibited by EU competition rules. To remove these concerns Aspen proposes to radically reduce its prices and to guarantee the supply of six critical cancer medicines. We now reach out to the stakeholders to hear their views on whether the commitments adequately address our concerns and benefit patients and health budgets across Europe.”
די פול דריקן מעלדונג און פֿראגן און ענטפֿערס זענען בנימצא אָנליין.
שער דעם אַרטיקל:
-
מאָטאָרינגקסנומקס טעג צוריק
פיאַט 500 ווס מיני קופּער: אַ דעטאַילעד פאַרגלייַך
-
Horizon Europeקסנומקס טעג צוריק
סוואַנסעאַ אַקאַדעמיקס אַוואָרדיד € 480,000 האָריזאָן אייראָפּע שענקען צו שטיצן נייַע פאָרשונג און כידעש פּרויעקט
-
לייפסטיילקסנומקס טעג צוריק
יבערמאַכן דיין לעבעדיק צימער: אַ בליק אין דער צוקונפֿט פון פֿאַרווייַלונג טעק
-
באַהאַמאַסקסנומקס טעג צוריק
באַהאַמאַס פיילז לעגאַל סאַבמישאַנז אויף קלימאַט ענדערונג מיט אינטערנאַציאָנאַלער קאָורט פון גערעכטיקייט